To: tuck who wrote (3123) | 4/23/2018 5:03:16 PM | From: tuck | | | Now the FDA AdCom vote. Two doses. 10-5 in favor of 2mg, and 10-5 against the 4mg on the risk-benefit metric. If approved, can the 2 mg dose make commercial inroads on competing products from PFE and ABBV?
Cheers, Tuck |
| Incyte (INCY) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
To: scaram(o)uche who wrote (3175) | 4/24/2018 11:56:50 AM | From: Miljenko Zuanic | | | Not clear is it JAK2 related, not related to platelets count (which actually decrease, not increase), so search for an answer not condemn drug in start. No trial can be executed to CONFIRM safety signal (not ETHICAL). So, THE ONLY WAY is REAL LIFE EXPERIENCE (controlled with BOX warning and proper management). Hope NEW FDA will be more open for suggestions!!??
Approval without option to increase dose, IF needed, is worthless. Some panel members had open mind, but they were in minority. |
| Incyte (INCY) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
To: scaram(o)uche who wrote (3177) | 4/24/2018 12:30:53 PM | From: Miljenko Zuanic | | | <How could any FDA be more liberal than the Gottlieb FDA?>
They (reviewers) had a chance to change how they should review revised application, but they did not. They kept old (from CRL) format focusing on 4 mg safety, not overall modality of approval, that LLY asked. 2 mg for overall population, refractory/failed methox, and bumping to 4mg for those who need MORE. FDA had a chance to dictate scope of discussion, but they did not!
That is my problem with FDA. I do not favor/disfavor with their decision, but how they come to conclusion is "problematic"!
I own INCY (after 301 fiasko, believe that Epa is not dead), and Bidi does not make thing any easy. |
| Incyte (INCY) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| |